| Friday June 19 |
| 08:00-08:40 |
Registration and coffee |
| 08:40-09:00 |
Welcome and Introduction |
| |
Oral session I |
Compliance and non-parametric modelling |
chair: Leon Aarons |
| 09:00-09:30 |
J.M. Gries |
Estimation of individual pharmacokinetic parameters in the presence of possible non-compliance |
| 09:30-10:00 |
D. Verotta |
Mechanistic and non-mechanistic drug dynamics modeling |
| 10:00-11:30 |
Poster and software session I |
| |
Oral session II |
Regulatory perspective |
chair: Janet Wade |
| 11:30-12:00 |
R. Shah |
Limitations of population approaches in regulatory assessment of new chemical entities. |
| 12:00-12:30 |
J. Wade |
Miscellaneous regulatory information |
| 12:30-14:00 |
Lunch |
| |
Oral session III |
Clinical applications |
chair: Karin Fattinger |
| 14:00-14:20 |
M. McFadyen |
Clinical versus statistical significance in covariate selection |
| 14:20-14:40 |
R. Gomeni |
Circadian population pharmacokinetics of 5-Fluorouracil in patients with metastatic colorectal cancer |
| 14:40-15:00 |
K. Kozlowski |
Semi-population model for analysis of infusable immunoglobin-G pharmacokinetics in VLBW infants |
| 15:00-15:20 |
S. Marshall |
Do we require the population approach to dose adjust in renal impairment?: A case study with dofetilide |
| 15:20-16:10 |
Coffee/Tea |
| |
Oral session IV |
Methodology |
chair: Mats Karlsson |
| 16:10-16:30 |
S. Duffull |
Comparison of a semiparametric method with NONMEM for population analysis of simulated data |
| 16:30-17:00 |
J. Wakefield |
The analysis of ordinal pharmacodynamic data: application to allergy score |
| 17:00-17:30 |
G. Graham |
A bayesian analysis of categorical and count pharmacodynamic data |
| |
| 19:00- 00:10 |
Social event |
Gut Höhne |
| |
| Saturday June 20 |
| |
Oral session V |
Methodology |
chair: Nick Holford |
| 09:00-09:20 |
M. Karlsson |
An automated stepwise covariate model building procedure within NONMEM |
| 09:20-09:40 |
R. Schoemaker |
Estimating potency for the Emax-model without attaining maximal effects |
| 09:40-10:00 |
S. Laporte |
What is the relevance of estimating inter-study variability in population pharmacokinetic meta-analysis? |
| 10:00-10:30 |
J.L. Steimer |
Mixed-effects modelling and simulation of the Dose-AUC relationship of saquinavir in healthy subjects and HIV-positive patients (II) |
| 10:30-12:00 |
Poster and software session II |
| |
Oral session VI |
Clinical trial simulation |
chair: Christian Pobel |
| 12:00-12:30 |
J. Mandema |
Dose ranging trials in detrusor instability with Tolterodine |
| 12:30-13:00 |
N. Holford |
Clinical Pharmacology = Disease Progress + Drug Action. The role of clinical trial modelling, simulation and analysis using the population PKPD approach |
| 13:00-13:30 |
M. Berahee |
An integrated population PK-PD model characterising the time course of exposure and clinical endpoints (biochemical, physiological and haemodynamics) for 546C88, a nitric oxide synthase inhibitor, in patients with septic shock |
| 13:30-13:40 |
Closure followed by light lunch |
Poster session I
GE Blakey, P McCormack, ADP Dean, N Entwistle An exploratory population pharmacokinetic analysis examining the influence of demography and co-medication on the plasma clearance of the anti-epileptic remacemide
S Chabaud, P Girard, P Nony , C. Laveille, JP Boissel PK-PD model of ivabradine, a bradzcardic agent, and ets metabolite in healthz volunteers
F Ezzet Population pharmacokinetics and therapeutic response of artemether following treatment of coartem in malaria patients
N Frey, M Dubar, JMA van Gervan, R Jochemsen Population pharmacokinetics/pharmacodynamics of rilmenidine in 27 hypertensive patients
JM Lanao, S Romano, MM Fdez De Gatta, MV Calvo, D Caballero, A Dominguez-Gil Population pharmacokinetics of amikacin in hematologic patients
P McCormack, L Aarons, N Yeates, M Nassim, J Gardner, M Russell Pharmacokinetic and pharmacodynamics of AR-C69931MX a novel P2T antagonist in healthy male and female volunteers
P Mismetti, S Laporte, P Girard, H Decousus Indirect pharmacodynamic model with two different markers of oral antocoagulant in young healthy volunteers
D Santos Buelga, G Frutos, MJ Garcia, MJ Otero, A Dominguez-Gil Optimization of a population pharmacokinetic model of theophylline in adult patients
N Simon, E Fuseau, P Daley-Yates Fluticasone propionate pharmacokinetics in asthma patients when administered alone or in combination to salmeterol
N Taright, F Mentré, P Engrand, F Loumaye, I Trinchard-Lugan, A Munafo Population pharmacokinetics of recombinant human luteinising hormone in patients
M Costa, E Berno, GP Zara, C Della Pepa, R Canaparo, M Eandi A non-parametric population PK/PD analysis of tolcapone to predict L-Dopa plasma concentrations
Poster session II
MJ García, D Santos Buelga, MJ Otero, B Blanco, AC Falcão, A Domínguez-Gil Therapeutic drug monitoring of antiepileptic drugs; can we use tdm data to estimate population pharmacokinetic parameters?
P Ghahramani, WW Yeo, GT Tucker Use of NONMEM to determine the influence of CYP2D6 activity on the pharmacokinetics of amitriptyline and nortriptyline
G Hempel, MO Karlsson, DP de Alwis, J McNay, N Toublanc, HG Schaefer Population PK/PD Modelling of 24h-Ambulatory Blood Pressure Data using NONMEM
M Van Guilder, R Leary, A Schumitzky, X Wang, S Vinks, R Jelliffe Nonlinear nonparametric population modeling on a supercomputer
I Meineke Modelling interoccasion variability after repeated oral drug administration
Y Merlé, E Schmautz, A Mallet Assessment of two strategies for detecting pharmacodynamic interactions in the context of the npml approach; Role of the design and of the interindividual variability
I Nestorov, L Aarons, M Rowland A population approach to the study of structure-pharmacokinetic relationships: An example with a homologous series of barbiturates
L Nguyen, P Variol, B Tranchand, C Puozzo Population pharmacokinetics of Navelbine : Model set up from phase I data and Validation of a limiting sampling strategy
P Noertersheuser, S Ghani, S Kreis Evaluation of the dose / concentration / response relationship of an antithrombotic acting development drug, performed with NONMEM and P - PHARM
U Wählby, EN Jonsson, MO Karlsson A stepwise procedure for interindividual variability model building
P Williams, J Lane, E Capparelli, C Turkel Computer Simulation: A Useful Tool for Trial Dosage Selection
